NCT06695026View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

December 18, 2024

Primary Completion Date

August 31, 2027

Study Completion Date

October 31, 2027

Conditions
Hepatocellular Carcinoma (HCC)
Interventions
DRUG

RZ-001 Dose 1

RZ-001 Dose 1 and VGCV, Atezolizumab/Bevacizumab

DRUG

RZ-001 Dose 2

RZ-001 Dose 2 and VGCV, Atezolizumab/Bevacizumab

DRUG

RZ-001 Dose 3

RZ-001 Dose 3 and VGCV, Atezolizumab/Bevacizumab

Trial Locations (9)

Unknown

RECRUITING

Pusan National University Yangsan Hospital, Busan

RECRUITING

Kyungpook National University Hospital, Daegu

RECRUITING

Catholic University of Korea, Seoul St. Mary's Hospital, Seoul

RECRUITING

Gangnam Severance Hospital, Seoul

RECRUITING

Kangbuk Samsung Medical Center, Seoul

RECRUITING

Korea University Guro Hospital, Seoul

RECRUITING

Samsung Medical Center, Seoul

RECRUITING

Seoul National University Hospital, Seoul

RECRUITING

Severance Hospital, Seoul

All Listed Sponsors
lead

Rznomics, Inc.

OTHER